Tenpoint Therapeutics’ Yuvezzi brings a combination approach to presbyopia compared to single mechanisms of action offered by once-daily eye drops from Orasis Pharmaceuticals, Lenz Therapeutics, and AbbVie. Yuvezzi’s commercialization will be supported by up to $235 million in financing.
Tenpoint Therapeutics’ name refers to the time it takes for an image to hit the retina and be processed by the brain. The regenerative medicine startup is developing cell therapies it hopes restore that vision capability for patients with degenerative eye disorders.
Discover the top AI-powered EAP providers for 2026. Compare platforms like Kyan Health and Spring Health on triage speed, global reach, and clinical quality to transform workforce wellbeing.